Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography

Elizabeth B. Agnew, Richard H. Wilson, Jean L. Grem, Leonard Neckers, Daoqin Bi, Chris H. Takimoto

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A sensitive HPLC assay has been developed to determine the concentration of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in human plasma over the concentration range of 12.5 to 2500 nM (7.33 to 1465 ng/mL). After the addition of 1000 nM geldanamycin as the internal standard, 1 mL samples of human plasma were subjected to solid-phase extraction, via Bond-Elut C18 cartridges, followed by analysis using an isocratic reversed-phase HPLC assay with UV detection. A Phenomenex Kingsorb, 3 micron, C18, 150×4.60 mm column and a Phenomenex Security Guard pre-column, C18 (ODS, Octadecyl), were used to achieve separation. AAG and GM were monitored at 334 and 308 nm, respectively, on a Hewlett-Packard 1050 Diode-Array Detector. The mobile phase, run at a flow-rate of 1 mL/min, was composed of 50% (v/v) 25 mM sodium phosphate (pH 3.00) with 10 mM triethylamine and 50% acetonitrile. HPLC effectively resolved AAG with retention times of 14.60±0.54 min and the internal standard geldanamycin at 10.72±0.38 min (n=15). This assay was able to measure plasma concentrations of AAG, the lower limit of quantitation being 12.5 nM, at a starting dose of 10 mg/m2 infused intravenously over 1 h in a Phase I clinical trial in adult patients with solid tumors.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume755
Issue number1-2
DOIs
StatePublished - May 5 2001

Fingerprint

tanespimycin
Plasma (human)
High performance liquid chromatography
Antineoplastic Agents
Assays
Tumors
Diodes
Flow rate
Detectors
Plasmas

Keywords

  • 17-(Allylamino)-17-demethoxygeldanamycin

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. / Agnew, Elizabeth B.; Wilson, Richard H.; Grem, Jean L.; Neckers, Leonard; Bi, Daoqin; Takimoto, Chris H.

In: Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 755, No. 1-2, 05.05.2001, p. 237-243.

Research output: Contribution to journalArticle

@article{b1d38d5f7b644891aff8ad33c2aa8eb5,
title = "Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography",
abstract = "A sensitive HPLC assay has been developed to determine the concentration of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in human plasma over the concentration range of 12.5 to 2500 nM (7.33 to 1465 ng/mL). After the addition of 1000 nM geldanamycin as the internal standard, 1 mL samples of human plasma were subjected to solid-phase extraction, via Bond-Elut C18 cartridges, followed by analysis using an isocratic reversed-phase HPLC assay with UV detection. A Phenomenex Kingsorb, 3 micron, C18, 150×4.60 mm column and a Phenomenex Security Guard pre-column, C18 (ODS, Octadecyl), were used to achieve separation. AAG and GM were monitored at 334 and 308 nm, respectively, on a Hewlett-Packard 1050 Diode-Array Detector. The mobile phase, run at a flow-rate of 1 mL/min, was composed of 50{\%} (v/v) 25 mM sodium phosphate (pH 3.00) with 10 mM triethylamine and 50{\%} acetonitrile. HPLC effectively resolved AAG with retention times of 14.60±0.54 min and the internal standard geldanamycin at 10.72±0.38 min (n=15). This assay was able to measure plasma concentrations of AAG, the lower limit of quantitation being 12.5 nM, at a starting dose of 10 mg/m2 infused intravenously over 1 h in a Phase I clinical trial in adult patients with solid tumors.",
keywords = "17-(Allylamino)-17-demethoxygeldanamycin",
author = "Agnew, {Elizabeth B.} and Wilson, {Richard H.} and Grem, {Jean L.} and Leonard Neckers and Daoqin Bi and Takimoto, {Chris H.}",
year = "2001",
month = "5",
day = "5",
doi = "10.1016/S0378-4347(01)00113-X",
language = "English (US)",
volume = "755",
pages = "237--243",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "1387-2273",
publisher = "Elsevier BV",
number = "1-2",

}

TY - JOUR

T1 - Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography

AU - Agnew, Elizabeth B.

AU - Wilson, Richard H.

AU - Grem, Jean L.

AU - Neckers, Leonard

AU - Bi, Daoqin

AU - Takimoto, Chris H.

PY - 2001/5/5

Y1 - 2001/5/5

N2 - A sensitive HPLC assay has been developed to determine the concentration of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in human plasma over the concentration range of 12.5 to 2500 nM (7.33 to 1465 ng/mL). After the addition of 1000 nM geldanamycin as the internal standard, 1 mL samples of human plasma were subjected to solid-phase extraction, via Bond-Elut C18 cartridges, followed by analysis using an isocratic reversed-phase HPLC assay with UV detection. A Phenomenex Kingsorb, 3 micron, C18, 150×4.60 mm column and a Phenomenex Security Guard pre-column, C18 (ODS, Octadecyl), were used to achieve separation. AAG and GM were monitored at 334 and 308 nm, respectively, on a Hewlett-Packard 1050 Diode-Array Detector. The mobile phase, run at a flow-rate of 1 mL/min, was composed of 50% (v/v) 25 mM sodium phosphate (pH 3.00) with 10 mM triethylamine and 50% acetonitrile. HPLC effectively resolved AAG with retention times of 14.60±0.54 min and the internal standard geldanamycin at 10.72±0.38 min (n=15). This assay was able to measure plasma concentrations of AAG, the lower limit of quantitation being 12.5 nM, at a starting dose of 10 mg/m2 infused intravenously over 1 h in a Phase I clinical trial in adult patients with solid tumors.

AB - A sensitive HPLC assay has been developed to determine the concentration of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in human plasma over the concentration range of 12.5 to 2500 nM (7.33 to 1465 ng/mL). After the addition of 1000 nM geldanamycin as the internal standard, 1 mL samples of human plasma were subjected to solid-phase extraction, via Bond-Elut C18 cartridges, followed by analysis using an isocratic reversed-phase HPLC assay with UV detection. A Phenomenex Kingsorb, 3 micron, C18, 150×4.60 mm column and a Phenomenex Security Guard pre-column, C18 (ODS, Octadecyl), were used to achieve separation. AAG and GM were monitored at 334 and 308 nm, respectively, on a Hewlett-Packard 1050 Diode-Array Detector. The mobile phase, run at a flow-rate of 1 mL/min, was composed of 50% (v/v) 25 mM sodium phosphate (pH 3.00) with 10 mM triethylamine and 50% acetonitrile. HPLC effectively resolved AAG with retention times of 14.60±0.54 min and the internal standard geldanamycin at 10.72±0.38 min (n=15). This assay was able to measure plasma concentrations of AAG, the lower limit of quantitation being 12.5 nM, at a starting dose of 10 mg/m2 infused intravenously over 1 h in a Phase I clinical trial in adult patients with solid tumors.

KW - 17-(Allylamino)-17-demethoxygeldanamycin

UR - http://www.scopus.com/inward/record.url?scp=0035810742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035810742&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(01)00113-X

DO - 10.1016/S0378-4347(01)00113-X

M3 - Article

C2 - 11393709

AN - SCOPUS:0035810742

VL - 755

SP - 237

EP - 243

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 1387-2273

IS - 1-2

ER -